Most expensive cancer drugs recently entering the European market do so without clear evidence of extending or improving quality of life, new research published in The BMJ has found.

See the source article by following the link below:
Most expensive cancer drugs recently entering the European market do so without clear evidence of extending or improving quality of life, new research published in The BMJ has found.